Anti-Human/Mouse Mac-2 (Galectin-3) (Clone M3/38 ) – Purified No Carrier Protein
Anti-Human/Mouse Mac-2 (Galectin-3) (Clone M3/38 ) – Purified No Carrier Protein
Product No.: M360
- -
- -
Clone M3/38 Target Mac-2 (Galectin-3) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody
Alternate Names Gal-3, RL-29, galactose-specific lectin 3, CBP-35, L-34 Isotype Rat IgG2a κ Applications ELISA , FC , IF , IHC , IP , WB |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human/Mouse Host Species Rat Immunogen Raised against galectin-3 of mouse origin Product Concentration 0.5 mg/ml Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. State of Matter Liquid Storage and Handling This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? ELISA, FC, IF, IHC, IP, WB Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity M3/38 activity is directed against human and mouse Mac-2 (Galectin-3).
Background Mac-2 (Galectin-3) is a β-galactoside-binding lectin of the chimera-type, characterized by a
single carbohydrate recognition domain and an N-terminal polypeptide tail region1. Mac-2 plays important roles in cell proliferation, apoptotic regulation, cell-to-cell and cell-to-matrix
interactions, macrophage activation, angiogenesis, inflammation, fibrosis and host defense.
Additionally, Mac-2 is an early-stage diagnostic and/or prognostic biomarker for viral infection,
neurodegenerative disorders, tumor formation, diabetes mellitus, and certain types of heart,
kidney, and autoimmune disease. The primary structure of mouse and human Mac-2 is highly
conserved with 85% similarity2. Human Mac-2 binds to asialofetuin and purified laminin. M3/38 was generated by immunizing rats with immunoadsorbent-purified macrophage glycoproteins and fusing the resulting spleen cells with mouse myeloma cells3. M3/38 is able to immunoprecipitate both the mouse and human Mac-2 homologs2,3. M3/38 binding to Mac-2 can be inhibited by galactose2. M3/38 recognizes a linear epitope within the N-terminal domain of Mac-24. The common minimal sequence as determined by SPOT analysis as Ala-Pro-Pro-Gly-Ala-Tyr. M3/38 has been exploited for live cell thyroid tumor imaging4,5. A chimeric M3/38 Fab-fragment and its humanized derivative can detect Mac-2 overexpression in cancerous thyroid nodules in mice via positron emission tomography. The three-dimensional structure of the rat/human chimeric Fab has been determined5. Antigen Distribution Mac-2 (Galectin-3) is expressed in the nucleus, cytoplasm, mitochondrion,
cell surface, and extracellular space. Mac-2 is secreted into fluids such as serum and urine as
well as released by injured and inflammatory cells. Mac-2 was originally identified in murine
inflammatory macrophages. Mac-2 is also expressed by various cell lines (e.g., HeLa, SL68,
HL60, HT29).
NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology References & Citations1 Hara A, Niwa M, Noguchi K, et al. Biomolecules. 10(3):389. 2020. 2 Cherayil BJ, Chaitovitz S, Wong C, et al. Proc Natl Acad Sci U S A. 87(18):7324-7328. 1990. 3 Ho MK, Springer TA. J Immunol. 128(3):1221-1228. 1982. 4 Peplau E, De Rose F, Eichinger A, et al. Sci Rep. 11(1):7358. 2021. 5 Peplau E, De Rose F, Reder S, et al. Thyroid. 30(9):1314-1326. 2020. 6 Flotte TJ, Springer TA, Thorbecke GJ. Am J Pathol. 111(1):112-24. 1983. 7 Nibbering PH, Leijh PC, van Furth R. Cell Immunol. 105(2):374-385. 1987. 8 Nibbering PH, Leijh PC, van Furth R. Immunology. 62(2):171-176. 1987. 9 Nibbering PH, van Furth R. Immunobiology. 176(4-5):432-439. 1988. 10 Nibbering PH, van der Heide A, van Furth R. J Pathol. 157(3):253-261. 1989. 11 Toussaint-Demylle D, Many MC, Theisen H, et al. Autoimmunity. 7(1):51-62. 1990. 12 Knisley KA, Weitlauf HM. J Reprod Fertil. 97(2):521-527. 1993. 13 Dumić J, Lauc G, Hadzija M, et al. Z Naturforsch C J Biosci. 55(3-4):261-266. 2000. 14 Mey A, Berthier-Vergnes O, Apoil PA, et al. Cancer Lett. 81(2):155-163. 1994. 15 Nachtigal M, Al-Assaad Z, Mayer EP, et al. Am J Pathol. 152(5):1199-1208. 1998. 16 Piantelli M, Iacobelli S, Almadori G, et al. J Clin Oncol. 20(18):3850-3856. 2002. 17 Schaffert C, Pour PM, Chaney WG. Int J Pancreatol. 23(1):1-9. 1998. 18 Dumic J, Lauc G, Flögel M. Cell Physiol Biochem. 10(3):149-158. 2000. 19 Dumić J, Barisić K, Flögel M, et al. Stress. 3(3):241-246. 2000. 20 Mey A, Leffler H, Hmama Z, et al. J Immunol. 156(4):1572-1577. 1996. Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
M361 | |
M363 | |
M360 | |
M362 |
![Disclaimer Alert Disclaimer Alert](/wp-content/themes/Avada-Child-Theme/disclaimer.jpg)